Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer
In patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (Xtandi), those who continued the treatment in combination with docetaxel and prednisolone saw improved progression-free survival (PFS), the phase IIIb PRESIDE study found. Median PFS was 9.53 months with the the enzalutamide-based combination compared with 8.28 months in those treated with placebo […]
Another PARP Inhibitor Active in BRCA-Mutant Prostate Cancer
A third of patients with previously treated BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) responded to the PARP inhibitor niraparib (Zejula), a prospective phase II study showed. The results showed that 26 of 76 patients with measurable disease had objective responses, 35 of whom had at least a 30% decrease in tumor size. An exploratory analysis […]
AI for Radiation Therapy Works, but Is it Fully Trusted?
The use of artificial intelligence in creating radiation treatment plans for prostate cancer appeared to be a success, according to a blinded, head-to-head study. Overall, radiation oncologists considered the vast majority — 89 of 100 — of machine learning (ML)-generated plans clinically acceptable for treatment, reported Thomas Purdie, PhD, and colleagues at Princess Margaret Cancer […]
What’s Guiding Prostate Cancer Care for Gay Men?
Prostate cancer isn’t just a research topic for B. R. Simon Rosser, PhD, MPH. It’s personal. Rosser, a pioneering researcher in HIV and LGBT health at the University of Minnesota School of Public Health in Minneapolis, was diagnosed with low-risk Gleason 6 prostate cancer in 2016, at the age of 57, and went on active […]
Some Beta Blockers Tied to Lower Recurrence Risk After Prostatectomy
Use of nonselective beta-blockers (nsBBs) at the time of radical prostatectomy may reduce the risk of prostate cancer recurrence, according to a Norwegian cohort study. Investigators found that use of nsBBs at the time of prostate cancer surgery was significantly associated with a 36% lower risk of receiving treatment for cancer recurrence, reported Shivanthe Sivanesan, […]
Can Prostate Cancer Patients on AS Delay Surgery at Progression?
Among men with clinically localized prostate cancer who continued active surveillance (AS) after biopsy progression, delaying surgery did not significantly reduce recurrence-free survival (RFS) rates or increase the risk of adverse pathology, researchers reported. In a prospectively followed cohort, men on AS who underwent early radical prostatectomy (RP) had a 3-year RFS rate of 80%, […]
In Early Prostate Cancer, Black Men Do Better With Radiotherapy Than White Men
Black men with localized prostate cancer had better treatment- and disease-specific outcomes than white men when treated with definitive radiotherapy, according to the results of a meta-analysis. Even though Black men were more likely to present with high-risk features, they were less likely to experience biochemical recurrence (subdistribution hazard ratio [sHR] 0.88, 95% CI 0.80-0.96, […]
NCCN Reverses on Guideline Change for Surveillance in Prostate Cancer
After protest by urologists and patient advocates, the prostate cancer panel of the National Comprehensive Cancer Network (NCCN) reversed itself on Tuesday, with new guideline language restoring active surveillance (AS) as a preferred approach for “most” men with low-risk prostate cancer. In September, the NCCN panel had published guidelines that eliminated the word “preferred” for […]
Are the Right Men Getting Screened for Prostate Cancer?
Prostate-specific antigen (PSA)-based screening for prostate cancer increased after the U.S. Preventive Services Task Force recommended individual decision-making for men ages 55 to 69 in 2017, reversing its 2012 guidance that advised against PSA screening in all men. Now, a retrospective cohort study found that from 2016 to 2019 the overall mean rate of PSA […]
Time for Targeted PSA Screening for Men With Rare Pathogenic Variants?
Men with certain pathogenic variants had a higher incidence of prostate cancer versus age-matched controls, and may be candidates for targeted prostate-specific antigen (PSA) screening, according to findings from the IMPACT trial. In the international, prospective study, men with confirmed pathogenic variants in mismatch repair (MMR) genes who underwent one screening round had a higher […]